204 related articles for article (PubMed ID: 12019088)
41. A Preclinical Model for Studying Herpes Simplex Virus Infection.
Tajpara P; Mildner M; Schmidt R; Vierhapper M; Matiasek J; Popow-Kraupp T; Schuster C; Elbe-Bürger A
J Invest Dermatol; 2019 Mar; 139(3):673-682. PubMed ID: 30414908
[TBL] [Abstract][Full Text] [Related]
42. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.
Gege C; Kleymann G
Expert Opin Ther Pat; 2022 Sep; 32(9):933-937. PubMed ID: 35965439
[TBL] [Abstract][Full Text] [Related]
43. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
Shiraki K; Yasumoto S; Toyama N; Fukuda H
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
[TBL] [Abstract][Full Text] [Related]
44. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
[TBL] [Abstract][Full Text] [Related]
45. A short commentary on the review by Weller and Kuchta: the DNA helicase-primase complex as a target for herpes virus infection.
Field HJ
Expert Opin Ther Targets; 2013 Oct; 17(10):1113-4. PubMed ID: 24044544
[No Abstract] [Full Text] [Related]
46. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo.
Hou J; Zhang Z; Huang Q; Yan J; Zhang X; Yu X; Tan G; Zheng C; Xu F; He S
BMC Infect Dis; 2017 Mar; 17(1):217. PubMed ID: 28320320
[TBL] [Abstract][Full Text] [Related]
47. Replacement of sulfonamide by sulfoximine within a helicase-primase inhibitor with restricted flexibility.
Gege C; Kleymann G
Bioorg Med Chem Lett; 2024 Jul; 106():129761. PubMed ID: 38642810
[TBL] [Abstract][Full Text] [Related]
48. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
49. Helicases as antiviral drug targets.
Frick DN
Drug News Perspect; 2003; 16(6):355-62. PubMed ID: 12973446
[TBL] [Abstract][Full Text] [Related]
50. The DNA helicase-primase complex as a target for herpes viral infection.
Weller SK; Kuchta RD
Expert Opin Ther Targets; 2013 Oct; 17(10):1119-32. PubMed ID: 23930666
[TBL] [Abstract][Full Text] [Related]
51. A novel oral vehicle for poorly soluble HSV-helicase inhibitors: PK/PD validations.
Duan J; Liard F; Paris W; Lambert M
Pharm Res; 2004 Nov; 21(11):2079-84. PubMed ID: 15587931
[TBL] [Abstract][Full Text] [Related]
52. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
James SH; Prichard MN
Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
[TBL] [Abstract][Full Text] [Related]
53. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.
Bernstein DI; Sawtell NM; Bravo FJ; Dixon DA; Gege C; Kleymann G
Antiviral Res; 2023 Nov; 219():105733. PubMed ID: 37858763
[TBL] [Abstract][Full Text] [Related]
54. Novel agents and strategies to treat herpes simplex virus infections.
Kleymann G
Expert Opin Investig Drugs; 2003 Feb; 12(2):165-83. PubMed ID: 12556212
[TBL] [Abstract][Full Text] [Related]
55. A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections.
Gege C; Bravo FJ; Uhlig N; Hagmaier T; Schmachtenberg R; Elis J; Burger-Kentischer A; Finkelmeier D; Hamprecht K; Grunwald T; Bernstein DI; Kleymann G
Sci Transl Med; 2021 Jun; 13(598):. PubMed ID: 34135112
[TBL] [Abstract][Full Text] [Related]
56. Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice.
Bhutta MS; Shechter O; Gallo ES; Martin SD; Jones E; Doncel GF; Borenstein R
Viruses; 2021 Jan; 13(1):. PubMed ID: 33435520
[TBL] [Abstract][Full Text] [Related]
57. Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus.
Tolo FM; Rukunga GM; Muli FW; Njagi EN; Njue W; Kumon K; Mungai GM; Muthaura CN; Muli JM; Keter LK; Oishi E; Kofi-Tsekpo MW
J Ethnopharmacol; 2006 Mar; 104(1-2):92-9. PubMed ID: 16198524
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]- guanine (A-5021) in mice.
Iwayama S; Ohmura Y; Suzuki K; Ono N; Nakazawa H; Aoki M; Tanabe I; Sekiyama T; Tsuji T; Okunishi M; Yamanishi K; Nishiyama Y
Antiviral Res; 1999 Jun; 42(2):139-48. PubMed ID: 10389656
[TBL] [Abstract][Full Text] [Related]
59. An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye.
Jaishankar D; Yakoub AM; Yadavalli T; Agelidis A; Thakkar N; Hadigal S; Ames J; Shukla D
Sci Transl Med; 2018 Feb; 10(428):. PubMed ID: 29444978
[TBL] [Abstract][Full Text] [Related]
60. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.
Birkmann A; Bonsmann S; Kropeit D; Pfaff T; Rangaraju M; Sumner M; Timmler B; Zimmermann H; Buschmann H; Ruebsamen-Schaeff H
J Med Chem; 2022 Oct; 65(20):13614-13628. PubMed ID: 36202389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
